Please login to the form below

Not currently logged in
Email:
Password:

BMS names chairman of the board

Giovanni Caforio to succeed Lamberto Andreotti on 2 May

BMS Giovanni CaforioBristol-Myers Squibb has selected its chief executive officer Giovanni Caforio to succeed Lamberto Andreotti as chairman of its board of directors from 2 May this year.

Caforio first joined BMS in 2000 as vice president and general manager of the company's operations in Italy, before taking on increasingly senior European positions.

He became senior vice president of global oncology and immunology in 2011, and was promoted to BMS' president of US pharmaceuticals later that year.

More recently, Caforio became an executive vice president and served as chief commercial officer and chief operating officer from 2013 and 2014, respectively.

Andreotti said: “Since being named chief executive officer, Giovanni has clearly demonstrated the capabilities needed to lead Bristol-Myers Squibb in the near and long term.

“It was a pleasure working with Giovanni during this transition period, and I have full confidence that he will do what is needed to continue to deliver on the company's mission and generate sustainable growth for our shareholders now and in the future.”

10th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics